Jazz Pharmaceuticals to Share Groundbreaking Ziihera Phase 3 Results at 2026 ASCO GI Symposium Jazz Pharmaceuticals is set to present important Phase 3 results for Ziihera® in two abstracts at the upcoming ASCO GI Symposium, highlighting advancements in treating HER2-positive gastroesophageal cancers.

Jazz Pharmaceuticals to Share Groundbreaking Ziihera Phase 3 Results at 2026 ASCO GI Symposium #United_States #San_Francisco #ZIIHERA #Jazz_Pharmaceuticals #HER2-positive

Positive HERIZON-GEA-01 Phase 3 Findings Support Ziihera as First-Line Treatment for HER2-Positive Cancer The Phase 3 HERIZON-GEA-01 trial shows Ziihera plus chemotherapy improves patient outcomes significantly for HER2-positive gastroesophageal adenocarcinoma.

Positive HERIZON-GEA-01 Phase 3 Findings Support Ziihera as First-Line Treatment for HER2-Positive Cancer #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #HER2

EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer - PMLiVE Approximately 26% of biliary tract cancer patients globally have HER2-positive disease

#gastrointestinalcancers #EC #JazzPharmaceuticals #Ziihera #zanidatamab #advancedbiliarytractcancer #biliarytractcancer #BTCpatients #HER2targetedbispecificantibody #HERIZONBTC01trial #gallbladdercancer #cholangiocarcinoma #advancedHER2positiveBTC #HER2targetedtherapy
pmlive.com/pharma_news/...

Jazz Pharmaceuticals Gains EU Approval for Ziihera® to Treat Advanced Biliary Tract Cancer Jazz Pharmaceuticals has received conditional EU marketing authorization for Ziihera® (zanidatamab), targeting advanced HER2-positive biliary tract cancer, providing hope for patients with limited treatment options.

Jazz Pharmaceuticals Gains EU Approval for Ziihera® to Treat Advanced Biliary Tract Cancer #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #biliary_tract_cancer

Jazz Pharmaceuticals Announces Encouraging Survival Data for Ziihera® in Cancer Treatment at ASCO 2025 Jazz Pharmaceuticals shared promising long-term survival data for Ziihera®, showing a median overall survival of 36.5 months in patients treated for HER2-positive metastatic gastroesophageal adenocarcinoma at ASCO 2025.

Jazz Pharmaceuticals Announces Encouraging Survival Data for Ziihera® in Cancer Treatment at ASCO 2025 #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #Zanidatamab

Jazz Pharmaceuticals to Host Investor Webcast on Ziihera® for Biliary Tract Cancer in December 2024 Join Jazz Pharmaceuticals on December 11, 2024, for a detailed webcast focusing on Ziihera®'s clinical data and commercialization strategy for biliary tract cancer treatment.

Jazz Pharmaceuticals to Host Investor Webcast on Ziihera® for Biliary Tract Cancer in December 2024 #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #zanidatamab-hrii

Jazz Pharmaceuticals Unveils Groundbreaking Research on Tumor Treatments at Upcoming Conferences Jazz Pharmaceuticals is set to showcase important research on solid tumors and blood cancer at major upcoming medical conferences, highlighting its commitment to innovation.

Jazz Pharmaceuticals Unveils Groundbreaking Research on Tumor Treatments at Upcoming Conferences #ZIIHERA #Ireland #Dublin #ASH_2024 #Jazz_Pharmaceuticals

Roche's PATHWAY HER2 Test Gains FDA Approval for Biliary Tract Cancer Patients Roche’s PATHWAY HER2 (4B5) test is now FDA-approved to identify biliary tract cancer patients eligible for HER2-targeted ZIIHERA treatment, improving care options.

Roche's PATHWAY HER2 Test Gains FDA Approval for Biliary Tract Cancer Patients #USA #Roche #ZIIHERA #PATHWAY_HER2 #Tucson